Impact of multiple comorbidities on long-term mortality in older patients following transcatheter aortic valve replacement

作者：Satoshi Higuchi, Hidenari Matsumoto, Ryota Masaki, Seita Kondo, Yasuhide Mochizuki, Shiori Fuse, Eiji Toyosaki, Tomoaki Masuda, Kazuto Maruta, Tadashi Omoto, Atsushi Aoki, Toshiro Shinke · 发表于：Heliyon · 年份：2024 · DOI：10.1016/j.heliyon.2024.e36724 · 被引用次数：2 · 研究领域：Cardiac Valve Diseases and Treatments、Aortic Disease and Treatment Approaches、Congenital Heart Disease Studies

Background: Older candidates for transcatheter aortic valve replacement (TAVR) frequently present with both cardiac and noncardiac comorbidities. There are few risk scores that evaluate a wide range of comorbidities. Methods: -statistics were assessed to compare the predictive abilities of the 3C score, the Charlson Comorbidities Index (CCI) score, the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II, and the Model for End-stage Liver Disease eXcluding International normalized ratio (MELD-XI) score. Results: -statistics of the 3C score, EuroSCORE II, MELD-XI score, and CCI score were 0.767 (0.666-0.867), 0.610 (0.491-0.729), 0.580 (0.465-0.696), and 0.476 (0.356-0.596), respectively (p < 0.001). Conclusions: Among cardiac and noncardiac comorbidities, special attention should be given to hepatobiliary system impairment and reduced LVEF in older patients following TAVR. The 3C score may contribute to the risk stratification.